SHANGHAI & SUZHOU, China & CAMBRIDGE, MA, USA I January 09, 2025 I Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic ...

HANGZHOU, China I January 10, 2025 I Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative ...

New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs ...

Mean IL-1Ra expression reached and maintained target levels in synovial fluid throughout six-month follow-up period ...

Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The programs are based on Leyden Labs’ ...

The FDA and European Medicines Agency (EMA) have granted several key designations to nipocalimab including: U.S. FDA Fast Track designation in hemolytic disease of the fetus and newborn (HDFN) and ...

OTTAWA, Canada I January 9, 2025 I Esphera SynBio, a pre-clinical stage synthetic biology company, today announced a new project aimed at advancing ...

SHANGHAI, China I January 9, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significant milestone ...

BEIJING, China & PRAGUE, Czech Republic I January 09, 2025 I Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing ...

NIEL, Belgium and BOSTON, MA, USA I January 9, 2025 I etherna immunotherapies NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based ...

In both clinical trials, lixudebart demonstrated a favorable safety profile, both as a monotherapy and in combination with standard of care (n=51 active patients across the two trials). These findings ...

PARIS, France I January 9, 2025 I Results from the investigational, randomized, open-label IRAKLIA phase 3 study demonstrated that Sarclisa administered at a ...